Trial Profile
Subclinical Inflammation, Myocardial Function and Fatty Acid Metabolism in Patients With Type 2 Diabetes and Heart Failure: Impact of a Short-term Treatment With Canagliflozin - a Pilot Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms Canacardia
- 20 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Oct 2017 New trial record